Being tested
B-cell depletion (anti-CD20): slow disability worsening in secondary progressive MS
secondary progressive MS · B-cell depletion (anti-CD20)
Trials are running now and no controlled trial has a readable result yet.
- Trials
- 8
- Running now
- 6
- Controlled phase 2/3 trials
- 2
- People in controlled trials
- 406
No controlled trial has reported a result yet.
Other linked trials: 8
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Other linked trials: 8
These linked trials do not set the status.
- CONSONANCE EXOngoing
Phase 3 · 2022 · Not randomised
- STOP-I-SEPOngoing
Phase 3 · 2019 · Compared with cyclophosphamide anhydrous, dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1a, interferon beta-1b, mycophenolate mofetil, natalizumab, teriflunomide
- CONSONANCEOngoing
Phase 3 · 2018 · Not randomised
- Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis PatientsNo result found
Phase 2/3 · 2017 · Not randomised
- MintakaOngoing
Phase 2 · 2026 · Placebo-controlled
- The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple SclerosisOngoing
Phase 2 · 2024 · Placebo-controlled
- ITT-PMS ExtResult in a paper, not read yet
Phase 2 · 2012 · Not randomised
Phase 1/2 · 2027 · Not randomised
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28Trials: 4 → 8
- 2026-10-28Trials: 3 → 4
- 2026-10-27First listed as Being tested
Related hypotheses
- B-cell depletion (anti-CD20): slow disability worsening in NMOSD
- B-cell depletion (anti-CD20): slow disability worsening in primary progressive MS
- B-cell depletion (anti-CD20): slow disability worsening in relapsing MS
- B-cell depletion (anti-CD20): slow disability worsening in relapsing and progressive MS
- B-cell depletion (anti-CD20): slow disability worsening in MS (type not specified)
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error